Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients

Exclusion Criteria

• •1. PS score 2-4;
• •2. Organ function impairment: FEV1 \<1000ml; absolute neutrophil count \<1.5×10\^9/L; platelets \<100×10\^9/L; hemoglobin \<90 g/ L; Serum creatinine clearance calculated according to Cockcroft-Gault formula \<50 mL/min; serum bilirubin\>1.5 times ULN; alanine aminotransferase and aspartate aminotransferase\>2.5 times ULN;
• •3. Unstable angina or myocardial infarction occurred in the past month;
• •4. Arrhythmia that has not been controlled and can cause symptoms or abnormal hemodynamics;
• •5. Active endocarditis;
• •6. Symptomatic severe aortic stenosis;
• •7. Heart failure that has not been controlled;
• •8. Acute pulmonary embolism, pulmonary infarction or low thrombosis (artery or vein) formation;
• •9. Suspected or confirmed aortic dissection;
• •10. Uncontrolled bronchial asthma;
• •11. Pulmonary edema;
• •12. Fingertip blood oxygen saturation at rest ≤85%;
• •13. Acute non-cardiopulmonary diseases (such as infection, renal failure, thyrotoxicosis, etc.) that may affect sports performance or aggravate due to exercise;
• •14. Mental disorders make it impossible to cooperate.
• •15. Patients for whom drug intervention is clearly recommended according to the 2022 edition of the European Society of Cardiology Guidelines on Cardio-Oncology.